Senolytic fisetin tested in RCT to reduce organ failure in sepsis patients

This is a phase II, multicenter randomized trial testing different doses of the senolytic drug fisetin in older patients with sepsis. The primary outcome is a composite score of cardiovascular, respiratory, and renal organ failure at 1 week. No results are reported in this abstract—only the study design, hypothesis, and intended outcomes are described.